Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio will present data at the Euretina Innovation Spotlight on September 30, 2026, and at Euretina in Vienna, Austria, October 1-4, 2026. The Euretina session features topline results from the Phase 3 DRAGON study of tinlarebant in adolescent Stargardt disease, presented by Michel Michaelides of Moorfields Eye Hospital.
Key figures
- Drug Name
- Tinlarebant (LBS-008)
- Phase Of Trial
- Phase 3
- Pdufa date
- February 12, 2027
- Nda accepted
- August 2026 with priority review
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.